Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMonica TaniGMGabriel ManSPSheel Patel

Discussion

Loading...

Member takes

Overview

Phase 1/1b trial shows 100% overall response rate in treatment-naive chronic lymphocytic leukemia, indicating effective combination therapy.

Key Points

  • Assess the safety and efficacy of zanubrutinib, obinutuzumab, and sonrotoclax in treatment-naive chronic lymphocytic leukemia.
  • Phase 1/1b dose-escalation study
  • Patients received zanubrutinib and obinutuzumab, with sonrotoclax introduced in Cycle 2
  • Endpoints included safety, overall response rate, and minimal residual disease status.
  • 100% overall response rate observed in efficacy-evaluable patients
  • 60% achieved complete response or complete response with incomplete marrow recovery
  • Median follow-up was 14.6 months with no progression-free survival events.

Cite This Study

Tani et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d86fhttps://doi.org/10.1182/blood-2025-3890
View Full Paper
Ask AI
Bookmark
Share